🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/Refractory Hematological Malignancies

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193Phase 18 sites📍 Zhengzhou📍 Suzhou📍 Suzhou Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tests: HDM2005 An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: OriV508 Injection Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site📍 Los Angeles Joshua Sasine, MD, PhD · Tests: autologous hematopoietic stem cells added to planned CAR T Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018Phase 11 site📍 Tianjin CytoCares Inc · Tests: CC312 Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone CD45BE-HSPC + CART-45 Cells NCT07451054Phase 11 site📍 Philadelphia University of Pennsylvania · Tests: CART-45 cells, CD45BE-HSPC A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies NCT07572006Phase 116 sites📍 Indianapolis📍 Grand Rapids📍 Piscataway Janssen Research & Development, LLC · Tests: JNJ-95804306, AML SoC, CLL/SLL SoC A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies NCT04283006EARLY Phase 11 site📍 Hangzhou He Huang · Tests: CD20/CD22 dual Targeted CAR T-cells A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies NCT07173595Phase 11 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: QLS2309 HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS NCT06731699Phase 11 site📍 Chengdu Chengdu FenDi Pharmaceutical Co., Ltd. · Tests: FD-001 A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) NCT03113643Phase 13 sites📍 Duarte📍 Boston📍 Houston Dana-Farber Cancer Institute · Tests: Azacitidine, SL-401, Venetoclax Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia NCT07014449Phase 11 site📍 Hangzhou Hangzhou Weben Pharma Co., Ltd · Tests: WBC100 QD SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: supCD7 CART cells CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors NCT07234110NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Fully human CD5 chimeric antigen receptor T cell injection In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma NCT07715630Phase 11 site📍 Kunming Chongqing Precision Biotech Co., Ltd · Tests: Invivo CAR-T A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies NCT04532203EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CAR-T cells, Ommaya Reservoir Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788Phase 145 sites📍 Gilbert📍 Los Angeles📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 Phase I Study of FXS0683 in the Treatment of Blood Tumors NCT07616089Phase 11 site📍 Tianjin Shanghai Fosun Pharmaceutical Industrial Development Co. Lt… · Tests: FXS0683 Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies NCT07584889Phase 1, Phase 21 site📍 Shenzhen Shenzhen University General Hospital · Tests: CAR-T cell Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) NCT03328078Phase 1, Phase 245 sites📍 Phoenix📍 Phoenix📍 Duarte Curis, Inc. · Tests: Emavusertib, Ibrutinib A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma NCT04634552Phase 278 sites📍 Birmingham📍 Little Rock📍 Duarte Janssen Research & Development, LLC · Tests: Talquetamab Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances NCT05110742Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients NCT05529069Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Pirtobrutinib, Venetoclax
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy